PubMed

Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes.

Pan HJ, Reifsnyder P, Vance DE, Xiao Q, Leiter EH.

Diabetes. 2005 Jun;54(6):1854-62.PMID: 15919809 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes.

Leiter EH, Reifsnyder PC, Zhang W, Pan HJ, Xiao Q, Mistry J.

Endocrinology. 2006 Feb;147(2):919-26. Epub 2005 Oct 27.PMID: 16254032 [PubMed - indexed for MEDLINE]Related articlesFree article

Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism.

Pan HJ, Lin Y, Chen YE, Vance DE, Leiter EH.

Vascul Pharmacol. 2006 Jul;45(1):65-71. Epub 2006 Jun 5.PMID: 16750656 [PubMed - indexed for MEDLINE]Related articles

Differential levels of diabetogenic stress in two new mouse models of obesity and type 2 diabetes.

Leiter EH, Reifsnyder PC.

Diabetes. 2004 Feb;53 Suppl 1:S4-11. Review.PMID: 14749259 [PubMed - indexed for MEDLINE]Related articlesFree article

Anti-insulin receptor autoantibodies are not required for type 2 diabetes pathogenesis in NZL/Lt mice, a New Zealand obese (NZO)-derived mouse strain.

McInerney MF, Najjar SM, Brickley D, Lutzke M, Abou-Rjaily GA, Reifsnyder P, Haskell BD, Flurkey K, Zhang YJ, Pietropaolo SL, Pietropaolo M, Byers JP, Leiter EH.

Exp Diabesity Res. 2004 Jul-Sep;5(3):177-85.PMID: 15512785 [PubMed - indexed for MEDLINE]Related articlesFree article

Maternal environment and genotype interact to establish diabesity in mice.

Reifsnyder PC, Churchill G, Leiter EH.

Genome Res. 2000 Oct;10(10):1568-78.PMID: 11042154 [PubMed - indexed for MEDLINE]Related articlesFree article

The diabetes-prone NZO/HlLt strain. I. Immunophenotypic comparison to the related NZB/BlNJ and NZW/LacJ strains.

Haskell BD, Flurkey K, Duffy TM, Sargent EE, Leiter EH.

Lab Invest. 2002 Jul;82(7):833-42.PMID: 12118085 [PubMed - indexed for MEDLINE]Related articles

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. Epub 2008 Feb 14.PMID: 18346728 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects.

Calkin AC, Forbes JM, Smith CM, Lassila M, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1903-9. Epub 2005 Jul 14.PMID: 16020748 [PubMed - indexed for MEDLINE]Related articlesFree article

Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.

Díaz-Delfín J, Morales M, Caelles C.

Diabetes. 2007 Jul;56(7):1865-71. Epub 2007 Apr 6.PMID: 17416798 [PubMed - indexed for MEDLINE]Related articlesFree article

Hyperglycemia, maturity-onset obesity, and insulin resistance in NONcNZO10/LtJ males, a new mouse model of type 2 diabetes.

Cho YR, Kim HJ, Park SY, Ko HJ, Hong EG, Higashimori T, Zhang Z, Jung DY, Ola MS, Lanoue KF, Leiter EH, Kim JK.

Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E327-36.PMID: 17616608 [PubMed - indexed for MEDLINE]Related articlesFree article

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice.

Reifsnyder PC, Leiter EH.

Diabetes. 2002 Mar;51(3):825-32.PMID: 11872687 [PubMed - indexed for MEDLINE]Related articlesFree article

Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease.

Wang CH, Leung CH, Liu SC, Chung CH.

J Formos Med Assoc. 2006 Sep;105(9):743-52.PMID: 16959622 [PubMed - indexed for MEDLINE]Related articlesFree article

Fatty liver and obesity: phenotypically correlated but genetically distinct traits in a mouse model of type 2 diabetes.

Itoi-Babaya M, Ikegami H, Fujisawa T, Ueda H, Nojima K, Babaya N, Kobayashi M, Noso S, Kawaguchi Y, Yamaji K, Shibata M, Ogihara T.

Diabetologia. 2007 Aug;50(8):1641-8. Epub 2007 Jun 5.PMID: 17549450 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone for type 2 diabetes mellitus.

Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006063. Review.PMID: 17636824 [PubMed - indexed for MEDLINE]Related articles

Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone.

Rong JX, Qiu Y, Hansen MK, Zhu L, Zhang V, Xie M, Okamoto Y, Mattie MD, Higashiyama H, Asano S, Strum JC, Ryan TE.

Diabetes. 2007 Jul;56(7):1751-60. Epub 2007 Apr 24.PMID: 17456854 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.

Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.

J Clin Endocrinol Metab. 2008 Jan;93(1):118-24. Epub 2007 Oct 23.PMID: 17956948 [PubMed - indexed for MEDLINE]Related articlesFree article

Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.

Hoo RL, Chow WS, Yau MH, Xu A, Tso AW, Tse HF, Fong CH, Tam S, Chan L, Lam KS.

Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2777-82. Epub 2007 Oct 11.PMID: 17932317 [PubMed - indexed for MEDLINE]Related articlesFree article

Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.

Osei K, Gaillard T, Schuster D.

Metabolism. 2007 Jan;56(1):24-9.PMID: 17161222 [PubMed - indexed for MEDLINE]Related articles